A randomised, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behcet's disease uveitis.

Trial Profile

A randomised, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behcet's disease uveitis.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs Gevokizumab (Primary)
  • Indications Behcet's syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms EYEGUARD-B
  • Sponsors Servier
  • Most Recent Events

    • 05 Oct 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 22 Jul 2015 According to a Xoma media release, this trial enrolled a total of 83 patients in the core part of the study (40 on gevokizumab and 43 on placebo). Patients were randomized when they reached the step of 20 mg/day equivalent oral prednisone and continued a standardized tapering regimen until they reached 5 mg/day during double-masked treatment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top